From DSM to ICN
Executive Summary
Former DSM Pharmaceuticals CEO Wesley Wheeler is named North American president of ICN Pharmaceuticals. Company notes that Wheeler has experience with "business turnarounds," cites his tenure at DSM. Wheeler joined the contract manufacturing firm as part of a management overhaul following several problematic FDA inspections. Prior to joining DSM, Wheeler was senior VP-logistics & strategy for GlaxoSmithKline (1"The Pink Sheet" Sept. 30, 2002, p. 30)...
You may also be interested in...
DSM Submits “Final” GMP Report To FDA; New Quality Systems In Place
DSM Pharmaceuticals is highlighting new environmental monitoring systems in its response to FDA about recent good manufacturing practices inspections
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.